Monthly information on share capital and company voting rights

Rhea-AI Summary

On September 10, 2021, Cellectis reported its share and voting rights data as of August 31, 2021. The company had a total of 45,465,310 shares in capital and 51,067,217 voting rights. Cellectis is a gene editing company specializing in CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. With over 21 years of expertise, it uses its TALEN® technology and PulseAgile system for therapeutic advancements. Cellectis aims to address blood disorders and cancers, enhancing its product pipeline.

Positive

• Cellectis has a robust pipeline with a focus on treating acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.
• The company is leveraging its TALEN® technology and PulseAgile system for innovative therapy development.
• Cellectis holds significant shares in capital and voting rights, indicating solid investor confidence.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
08/31/2021	45,465,310	51,067,217

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.

Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com   
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

IR contact:
Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investors@cellectis.com

Attachment

• Voting_Rights_PR_August_EN_docx

FAQ

What are the total shares and voting rights for Cellectis as of August 31, 2021?

As of August 31, 2021, Cellectis had 45,465,310 shares in capital and 51,067,217 voting rights.

What is Cellectis's focus in gene editing?

Cellectis focuses on developing off-the-shelf CAR-T immunotherapies and therapeutic gene editing for various diseases, including cancers.

What gene editing technology does Cellectis use?

Cellectis utilizes TALEN® gene editing technology and the PulseAgile electroporation system.

In which markets is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).